HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

1. Industry viewpoints:<ul>
<li>It is expected that the market size of IBD (Inflammatory Bowel Disease) drug therapy in China would keep growing in the next five years.</li>
<li>Since COVID-19 virus was detected in imported reagents this time, considering safety factors, the trend of import substitution for reagent varieties is expected to accelerate.</li>
<li>In the field of high-end antibiotics, Chinese enterprises have yet to make breakthroughs.</li>
</ul>2. Company news:News about the progress of new drugs from <a href="https://www.smartkarma.com/entities/beigene-ltd" target="_blank" data-smartkarma-citation="entities:27352:1" rel="noopener">BeiGene Ltd (6160 HK)</a>, <a href="https://www.smartkarma.com/entities/harbour-biomed-holdings-limited" target="_blank" data-smartkarma-citation="entities:29717:1" rel="noopener">Harbour Biomed (2142 HK)</a>, <a href="https://www.smartkarma.com/entities/antengene-corp-ltd" target="_blank" data-smartkarma-citation="entities:29705:1" rel="noopener">Antengene (6996 HK)</a> and <a href="https://www.smartkarma.com/entities/shanghai-junshi-bioscience-h" target="_blank" data-smartkarma-citation="entities:27760:1" rel="noopener">Shanghai Junshi Bioscience Co. Ltd. (1877 HK)</a>.3. Market review:Last week, stock price for healthcare sector in A share decreased 7.1%, while CSI 300 decreased 3.91% over the same period of time.4. Risk disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints:
It is expected that the market size of IBD (Inflammatory Bowel Disease) drug therapy in China would keep growing in the next five years.
Since COVID-19 virus was detected in imported reagents this time, considering safety factors, the trend of import substitution for reagent varieties is expected to accelerate.
In the field of high-end antibiotics, Chinese enterprises have yet to make breakthroughs.
2. Company news:News about the progress of new drugs from BeiGene Ltd (6160 HK), Harbour Biomed (2142 HK), Antengene (6996 HK) and Shanghai Junshi Bioscience Co. Ltd. (1877 HK).3. Market review:Last week, stock price for healthcare sector in A share decreased 7.1%, while CSI 300 decreased 3.91% over the same period of time.4. Risk disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

China

Zhejiang Xianju Pharmaceutical Company Ltd. produces corticosteroids, hormones, and progesterone hormone drugs.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zhejiang Xianju Pharma A (002332 CH)

China Healthcare Weekly (Jan.29)

The article analyzed industry viewpoints in terms of IBD drug therapy, import substitution for reagent varieties and high-end antibiotics market,...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)